BRIEF-Abbvie receives U.S. FDA approval of supplemental new drug application for Viekira Pak without Ribavirin

* Abbvie receives u.s. Fda approval of supplemental new drug application for viekira pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin in genotype 1b chronic hepatitis c patients with compensated cirrhosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.